U.S. Professional Services Stock News

In early April 2026, NASA’s Orion spacecraft, built by Lockheed Martin, successfully launched the crewed Artemis II mission from Kennedy Space Center, carrying four astronauts on a 10-day journey around Earth and beyond the far side of the Moon with upgraded life support, controls, and safety systems. This mission highlights how Lockheed Martin’s space technology work sits alongside its expanding missile and aircraft programs, underscoring its role across both deep-space exploration and...

If you are wondering whether Clearway Energy's share price still offers value after a strong run, the key is understanding what the current market price might already be factoring in. The stock last closed at US$39.64, with returns of 1.2% over 7 days, 12.7% over 30 days, 23.4% year to date, 68.3% over 1 year, 58.3% over 3 years and 94.3% over 5 years. This raises the question of how much of the story is already reflected in the valuation. Recent news around Clearway Energy has focused on...

Investors may be wondering whether Sprouts Farmers Market is still priced attractively after recent volatility, or if the easy value has already been taken off the table. The stock closed at US$77.12, with returns of 0% over 7 days, a 3.9% decline over 30 days, a 4.4% decline year to date, a 46.7% decline over 1 year, but gains of 123.9% over 3 years and 182.9% over 5 years. Recent attention on Sprouts Farmers Market has focused on its longer term share price track record compared with more...

In its latest results, WillScot Holdings reported a 13% year-over-year decline in EBITDA, a similar drop in units on rent, and wrote off about 15% of its rental fleet, underscoring mounting financial and operational pressure. These fleet impairments and signs of tougher competition, particularly from United Rentals, point to a business mix tilting toward smaller, less profitable segments. Against this backdrop of fleet write-offs and weakening core metrics, we will assess how the news...

Why Brookfield Wealth Solutions is on investors’ radar today Brookfield Wealth Solutions (BNT) has been drawing attention after a period where the share price shows mixed returns across different time frames. This has prompted closer scrutiny of its business mix and current valuation. See our latest analysis for Brookfield Wealth Solutions. The latest 1 day share price return of a 0.4% decline and 90 day share price return of a 12% decline contrast with a 1 year total shareholder return of...

In recent weeks, Alliant Energy announced a US$1.00 billion at-the-market equity offering to fund data center and AI/cloud-related infrastructure, alongside governance changes such as a mandatory director retirement age of 70 and a target of 75% independent board representation. The same initiatives have drawn rising environmental and community opposition in Wisconsin and Iowa, highlighting that Alliant’s push into digital infrastructure could reshape both its growth profile and its...

Ultragenyx Pharmaceutical (RARE) is back in focus after the FDA accepted its resubmitted biologics license application for UX111, a gene therapy for Sanfilippo syndrome Type A, with an accelerated approval decision expected later this year. See our latest analysis for Ultragenyx Pharmaceutical. The FDA milestones around UX111 and UX016 have arrived against a mixed backdrop, with a sharp 18.5% 7 day share price return contrasting with a 1 year total shareholder return of 28.84% and a 5 year...

Corteva recently reached a new all-time high, supported by overwhelmingly positive analyst sentiment that now skews toward “Buy” ratings from major firms. Low short interest and strong participation from both Wall Street and individual investors highlight how sentiment alone can materially influence Corteva’s trading activity. We’ll now explore how this wave of bullish analyst support could reshape Corteva’s investment narrative and perceived risk-reward balance. This technology could...

Green Brick Partners (GRBK) is drawing fresh investor attention after announcing Rainwater Crossing, a master planned community in Celina, Texas that combines new model homes, multiple builders, extensive amenities and public art. See our latest analysis for Green Brick Partners. Alongside the Rainwater Crossing announcement, Green Brick Partners’ share price has moved to US$66.26, with a 7 day share price return of 5.59% but a 30 day share price return of a 3.00% decline. The 1 year total...

Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly. The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in. Recent coverage has focused on Vera Therapeutics as investors...

Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention. See our latest analysis for Align Technology. At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year...

In late March 2026, Guardant Health announced that its InfinityAI real-world evidence platform was used alongside clinical trial data to support Japan’s approval of Daiichi Sankyo’s ENHERTU for treating HER2-positive advanced or recurrent solid cancers refractory or intolerant to standard therapies. This use of InfinityAI highlights how Guardant’s clinicogenomic data and artificial intelligence can help regulators assess outcomes in genomic subpopulations that are difficult to enroll in...

Celcuity Inc. recently reported fourth-quarter 2025 results showing a net loss of US$50.97 million, with basic loss per share from continuing operations of US$0.97, and a full-year 2025 net loss of US$177.04 million, or US$3.79 per share, both higher than the prior year. The sharp year-on-year increase in reported net loss highlights the cost of Celcuity’s ongoing development and commercialization efforts as it remains a pre-revenue, clinical-stage biotechnology company. With losses widening...

Casella Waste Systems stock moves after recent share performance Casella Waste Systems (CWST) has caught investor attention after a mixed recent run, with the stock up around 10% over the past week but showing declines over the month and past 3 months. See our latest analysis for Casella Waste Systems. At a share price of $86.23, Casella’s recent 10% 7 day share price return contrasts with weaker 1 month and year to date share price returns. The 1 year total shareholder return of 17.11% and 5...

Rhythm Pharmaceuticals recently received a positive opinion from the European Medicines Agency’s CHMP to expand IMCIVREE’s authorization to acquired hypothalamic obesity, and appointed veteran life sciences leader Kim Popovits to its Board, succeeding Ed Mathers. This combination of potential European label expansion for IMCIVREE and added commercialization expertise on the Board may meaningfully influence how Rhythm executes its rare neuroendocrine disease focus. Next, we’ll examine how the...

Some AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders may be a little concerned to see that the Independent Director, John...

Check Point Software Technologies Ltd. ( NASDAQ:CHKP ) just reported some strong earnings, and the market reacted...

If you are wondering whether Louisiana-Pacific at around US$72 a share is offering good value or is already pricing in a lot of expectations, this article will help you frame that question using several valuation lenses. The stock has been choppy recently, with a 2.6% gain over the last 7 days, a 7.2% decline over 30 days, and year-to-date returns showing an 11.7% decline, while the 3-year and 5-year returns sit at 35.5% and 22.4% respectively. Recent attention on Louisiana-Pacific has...

Installed Building Products recently reported fourth-quarter earnings per share of US$3.24, beating expectations while revealing a 9% sales decline in its residential segment and announcing a new US$500 million share repurchase program alongside higher dividends. Management also reduced near-term revenue guidance and cited severe winter weather as a key factor pressuring residential insulation demand, even as commercial activity and acquisition efforts provided a partial offset. Next, we’ll...

If you are wondering whether QuidelOrtho's current share price reflects its underlying value, this article walks through the key numbers that investors tend to focus on before making a decision. QuidelOrtho last closed at US$15.88, with returns of 4.1% over the past week, a 23.8% decline over the past month, and year to date and 1 year returns of 44.8% and 44.0% declines respectively. The 3 year and 5 year returns sit at 82.5% and 87.5% declines. These moves come as investors reassess the...

Amdocs recently extended its long-term relationship with T-Mobile under a new multi-year agreement covering managed services, software development, and AI innovation, while also expanding its engagement with Vodafone Germany, adding two western European clients, completing the Matrixx Software acquisition, and unveiling its telecom-focused aOS agentic operating system. Together, these moves point to Amdocs deepening its role at large carriers and broadening its telecom software capabilities...

In March 2026, Johnson & Johnson announced a US$500 million R&D co-funding agreement with Royalty Pharma across 2026 and 2027 to advance JNJ-4804, a novel co-antibody therapy targeting both IL-23 and TNF pathways in autoimmune diseases. This collaboration gives Royalty Pharma exposure to an early-stage, dual-pathway autoimmune candidate that could meaningfully influence the mix and risk profile of its royalty portfolio. Next, we’ll examine how this substantial R&D co-funding commitment...

In its fourth-quarter 2025 investor letter, TimesSquare Capital’s U.S. Small Cap Growth Strategy highlighted NewAmsterdam Pharma’s CETP inhibitor program for cardiovascular patients, citing strongly positive indications ahead of trial readouts. This attention underscores how emerging data around LDL-lowering CETP inhibitors can quickly elevate a smaller biopharma company’s profile within the cardiovascular treatment landscape. We’ll now examine how growing optimism around NewAmsterdam...

The United States market has experienced a notable upswing, climbing 4.4% in the last week and an impressive 32% over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be undervalued requires a keen eye for potential growth and resilience amidst broader market gains, as highlighted by companies like BillionToOne and others.